Recursion Pharmaceuticals Inc (RXRX)
6.91
-0.41
(-5.60%)
USD |
NASDAQ |
Nov 14, 16:00
6.85
-0.06
(-0.87%)
After-Hours: 04:54
Recursion Pharmaceuticals Research and Development Expense (Quarterly): 74.60M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 74.60M |
| June 30, 2024 | 73.93M |
| March 31, 2024 | 67.56M |
| December 31, 2023 | 69.48M |
| September 30, 2023 | 70.01M |
| June 30, 2023 | 55.06M |
| March 31, 2023 | 46.68M |
| December 31, 2022 | 43.98M |
| September 30, 2022 | 40.84M |
| June 30, 2022 | 38.44M |
| Date | Value |
|---|---|
| March 31, 2022 | 32.44M |
| December 31, 2021 | 48.29M |
| September 30, 2021 | 33.25M |
| June 30, 2021 | 29.62M |
| March 31, 2021 | 24.11M |
| December 31, 2020 | 20.70M |
| September 30, 2020 | 16.54M |
| June 30, 2020 | 13.24M |
| March 31, 2020 | 12.84M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
12.84M
Minimum
Mar 2020
74.60M
Maximum
Sep 2024
42.72M
Average
40.84M
Median
Sep 2022
Research and Development Expense (Quarterly) Benchmarks
| Revance Therapeutics Inc | 11.38M |
| Eli Lilly and Co | 2.734B |
| Pfizer Inc | 2.598B |
| Twist Bioscience Corp | 22.47M |
| NovaBay Pharmaceuticals Inc | 0.004M |